Skip to main content

Table 7 Incremental cost-effectiveness ratios in 2002 prices for the preferred (not dominated) strategies from Bolin et al. [10], assuming a 10-year dwell time

From: Re-interpreting the data on the cost and effectiveness of population screening for colorectal cancer in Australia

Strategy Cost ($) Incremental changes in cost ($) Effectiveness (LYG) Incremental changes in effectiveness (LYG) Average cost-effectiveness ratio ($) Incremental cost-effectiveness ratio ($)
  (a) (b) (c) (d) (a)/(c) (b)/(d)
EXISTING PRACTICE 0   0   (Undefined)  
FOBT2 140,117,791 140,117,791 3,551 3,551 39,459 39,459
DCBE5 248,112,291 107,994,500 6,023 2,472 41,194 43,687
DCBE3 304,301,903 56,189,612 6,720 697 45,283 80,616
FOBT1+DCBE5 370,181,240 65,879,337 7,076 356 52,315 185,054
FOBT1+DCBE3 422,777,702 52,596,462 7,299 223 57,923 235,859
  1. Note: Other options rejected on the grounds of 'simple' and 'extended' dominance, see text for a discussion